Gruen P G, Sachar E J, Altman N, Langer G, Tabrizi M A, Halpern F S
Arch Gen Psychiatry. 1978 Oct;35(10):1222-7. doi: 10.1001/archpsyc.1978.01770340072008.
It has been suggested that, if dopamine antagonism is a necessary condition for the antischizophrenic action of neuroleptics, the prolactin response, as an index of dopamine blockade, would correlate with clinical response. Morning prolactin and clinical symptomatology were measured in 15 schizophrenic patients before neuroleptic therapy, and after three and six weeks of high-dose butaperazine or loxapine treatment. Prolactin levels were transiently elevated during the unmedicated admission period, probably reflecting a normal stress response. Prolactin increased in all patients during neuroleptic therapy. There was, however, no correlation between magnitude of prolactin changes and clinical response, probably because the prolactin response achieved a maximum at relatively low doses of neuroleptics.
有人提出,如果多巴胺拮抗作用是抗精神病药物抗精神分裂症作用的必要条件,那么作为多巴胺阻断指标的催乳素反应将与临床反应相关。在15例精神分裂症患者接受抗精神病药物治疗前、以及接受高剂量丁酰拉嗪或洛沙平治疗3周和6周后,测量了其早晨催乳素水平和临床症状。在未用药的入院期间,催乳素水平短暂升高,这可能反映了正常的应激反应。在抗精神病药物治疗期间,所有患者的催乳素水平均升高。然而,催乳素变化幅度与临床反应之间没有相关性,这可能是因为在相对较低剂量的抗精神病药物作用下,催乳素反应已达到最大值。